FDA Extends LEQEMBI Review Period, Impacting Biogen's Market Strategy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 08 2026
0mins
Should l Buy BIIB?
Source: NASDAQ.COM
Biogen Inc's stock rose by 3.11% as it reached a 52-week high amid positive market conditions, with the Nasdaq-100 up 1.19% and the S&P 500 up 0.72%.
The FDA has extended the review period for Biogen's LEQEMBI by three months, with a new action date set for August 24, 2026. This extension allows for a thorough review of additional materials, which may impact the drug's market entry timeline. Biogen and Eisai believe that the comprehensive clinical data package for LEQEMBI supports its potential use as an initiation therapy for early Alzheimer's disease, which could enhance market competitiveness and provide patients with more treatment options.
This FDA review extension may lead to short-term volatility in Biogen's stock price, as investor expectations are closely tied to the approval timeline of LEQEMBI. The companies may need to adjust their market strategies in response to this regulatory scrutiny.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BIIB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BIIB
Wall Street analysts forecast BIIB stock price to rise
26 Analyst Rating
11 Buy
14 Hold
1 Sell
Moderate Buy
Current: 191.370
Low
143.00
Averages
204.45
High
246.00
Current: 191.370
Low
143.00
Averages
204.45
High
246.00
About BIIB
Biogen Inc. is a biotechnology company. The Company is focused on discovering, developing and delivering therapies. It has a portfolio of medicines to treat Multiple Sclerosis (MS), has introduced an approved treatment for Spinal Muscular Atrophy (SMA), co-developed treatments to address a defining pathology of Alzheimer’s disease and launched an approved treatment to target a genetic cause of Amyotrophic Lateral Sclerosis (ALS). It markets a drug approved in United States, European Union and certain international markets for the treatment of Friedreich Ataxia (FA) in adults and adolescents aged 16 years and older. It is focused on advancing its pipeline in neurology, specialized immunology and rare diseases. Its marketed products include VUMERITY, TYSABRI, TECFIDERA, AVONEX and PLEGRIDY for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of FA, and QALSODY for the treatment of ALS. Its commercialized products also include EMPAVELI and SYFOVRE.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biogen Advances Alzheimer’s Drug Development Despite Primary Endpoint Miss
- Clinical Trial Results: Biogen's 18-month placebo-controlled study demonstrated significant reductions in tau levels across all tested doses, and although it missed the primary endpoint, the overall biomarker and clinical efficacy data were robust enough to support advancement into registrational development.
- Safety Analysis: The treatment's safety profile was largely consistent with earlier studies, although higher serious adverse events were noted at the highest dose, indicating a need for caution in dose selection moving forward.
- Market Reaction: Biogen's shares surged over 7% in pre-market trading on Tuesday, positioning the stock for its highest level in nearly two years, reflecting positive market sentiment towards its experimental Alzheimer’s therapy.
- Future Plans: Biogen intends to present detailed data at the Alzheimer’s Association International Conference (AAIC) from July 12-15, 2026, further advancing the drug's registration application process.
See More
Investment Opportunities in Biogen and Novo Nordisk: A Comparative Analysis
- Biogen's Turnaround Potential: Biogen focuses on neurology, and despite declining revenue from its multiple sclerosis products, Q1 2025 revenue rose 2% year-over-year to $2.5 billion, with Leqembi sales increasing 74% to $168 million, indicating significant market potential in Alzheimer's treatment.
- Acquisition-Driven Pipeline Expansion: By acquiring Reata Pharmaceuticals for $7.3 billion and Apellis Pharmaceuticals for $5.6 billion, Biogen has introduced new drugs like Skyclarys and Empaveli, with projected sales growth in the low to mid-teens through 2028, enhancing its product diversity.
- Novo Nordisk's Growth Engine: Novo Nordisk excels in diabetes and obesity markets, reporting Q1 2025 revenue of 96.8 billion DKK (approximately $15.3 billion), a 24% year-over-year increase, driven by high demand for its GLP-1 drugs, prompting the company to expand manufacturing capacity for sustained competitiveness.
- Diversification Strategy: Novo Nordisk's $4.7 billion acquisition of Akero Therapeutics strengthens its metabolic treatment portfolio, while label expansions for its GLP-1 therapies in cardiovascular and chronic kidney disease treatments enhance clinical versatility, solidifying its competitive position in the healthcare insurance market.
See More
Biogen Advances Alzheimer's Drug to Late-Stage Testing Despite Mixed Results
- Clinical Trial Progress: Biogen announced its plan to advance an experimental Alzheimer's drug to Phase 3 testing despite disappointing mid-stage trial results, as it shows potential in reducing tau protein levels and slowing cognitive decline, particularly at the lowest dose.
- Drug Development Challenges: The company has faced setbacks in its Alzheimer's drug development journey, having successfully launched two drugs to slow cognitive decline, yet its first drug, Aduhelm, was withdrawn due to approval controversies, highlighting market uncertainties.
- Scientific Basis: Biogen's head of development, Dr. Priya Singhal, stated that the latest trial results demonstrate an unprecedented combination of tau reduction and cognitive benefits, emphasizing the necessity to move to Phase 3 testing, indicating progress in dose isolation.
- Competitive Landscape: In the Alzheimer's treatment arena, Biogen faces pressure from rival Eli Lilly, which is also studying drugs aimed at decreasing tau protein levels, underscoring the intense market competition and the urgent demand for innovative therapies.
See More
Bitcoin-Linked Stocks Rise as Starbucks Gets Upgrade
- Bitcoin-Linked Stocks Rise: Bitcoin rose 2% as the Senate Banking Committee discussed a regulatory framework for cryptocurrencies, with Coinbase shares jumping nearly 9%, indicating growing market confidence that could drive future growth for related companies.
- Starbucks Upgrade: TD Cowen upgraded Starbucks from hold to buy, raising its price target from $106 to $120, with analysts noting multiple positive sales drivers in a strong market backdrop, suggesting improved performance ahead.
- Ford Stock Surge: Ford shares rose 7%, adding to a 13% gain from Wednesday, as Morgan Stanley highlighted its energy storage business and partnership with CATL, projecting a $3 billion incremental revenue opportunity for Ford's Model e segment.
- Applied Materials Earnings Outlook: Applied Materials saw a 2% increase in shares ahead of its fiscal second-quarter results, with analysts expecting earnings of $2.66 per share and revenue of $7.68 billion, reflecting sustained optimism about semiconductor equipment demand.
See More
Biogen Advances Alzheimer's Drug to Late-Stage Testing Despite Mixed Results
- Clinical Trial Progress: Biogen announced its plan to advance an experimental Alzheimer's drug into Phase 3 testing despite disappointing mid-stage results, as signals from the lowest dose suggest potential tau reduction and cognitive decline slowing, indicating the drug's development value.
- Mechanism of Action: The drug Diranersen is an antisense oligonucleotide aimed at limiting tau protein production; although higher doses did not show better responses, the efficacy at lower doses provides hope for further research and could pave the way for new Alzheimer's treatments.
- R&D Challenges and Opportunities: Biogen has faced numerous setbacks in developing Alzheimer's drugs, with its first drug Aduhelm withdrawn due to controversy, yet the company remains committed to advancing new therapies, demonstrating resilience in this challenging field.
- Competitive Landscape: As Biogen pushes forward with its drug, rival Eli Lilly is also studying drugs aimed at decreasing tau levels, highlighting the intensifying competition in Alzheimer's treatment, necessitating Biogen to accelerate its R&D efforts to maintain market leadership.
See More
Biogen Completes Acquisition of Apellis Pharmaceuticals
- Acquisition Finalized: Biogen has successfully completed the acquisition of Apellis Pharmaceuticals, which is now a wholly owned subsidiary, significantly enhancing Biogen's market position in nephrology and expected to drive future revenue growth.
- Product Value Addition: Apellis' two products, EMPAVELI® and SYFOVRE®, generated $689 million in net product revenue in 2025, which is anticipated to positively impact Biogen's non-GAAP diluted EPS, enhancing its future profitability.
- Accelerated Market Readiness: The acquisition allows Biogen to leverage Apellis' established commercial and medical infrastructure to expedite the launch readiness for felzartamab, with the first Phase 3 trial readout expected in the first half of 2027.
- Enhanced Shareholder Returns: This transaction is expected to increase Biogen's non-GAAP EPS compound annual growth rate (CAGR), positively impacting its financial performance in 2027 and further boosting investor confidence.
See More
Biogen Advances Alzheimer’s Drug Development Despite Primary Endpoint Miss
- Clinical Trial Results: Biogen's 18-month placebo-controlled study demonstrated significant reductions in tau levels across all tested doses, and although it missed the primary endpoint, the overall biomarker and clinical efficacy data were robust enough to support advancement into registrational development.
- Safety Analysis: The treatment's safety profile was largely consistent with earlier studies, although higher serious adverse events were noted at the highest dose, indicating a need for caution in dose selection moving forward.
- Market Reaction: Biogen's shares surged over 7% in pre-market trading on Tuesday, positioning the stock for its highest level in nearly two years, reflecting positive market sentiment towards its experimental Alzheimer’s therapy.
- Future Plans: Biogen intends to present detailed data at the Alzheimer’s Association International Conference (AAIC) from July 12-15, 2026, further advancing the drug's registration application process.
See More
Investment Opportunities in Biogen and Novo Nordisk: A Comparative Analysis
- Biogen's Turnaround Potential: Biogen focuses on neurology, and despite declining revenue from its multiple sclerosis products, Q1 2025 revenue rose 2% year-over-year to $2.5 billion, with Leqembi sales increasing 74% to $168 million, indicating significant market potential in Alzheimer's treatment.
- Acquisition-Driven Pipeline Expansion: By acquiring Reata Pharmaceuticals for $7.3 billion and Apellis Pharmaceuticals for $5.6 billion, Biogen has introduced new drugs like Skyclarys and Empaveli, with projected sales growth in the low to mid-teens through 2028, enhancing its product diversity.
- Novo Nordisk's Growth Engine: Novo Nordisk excels in diabetes and obesity markets, reporting Q1 2025 revenue of 96.8 billion DKK (approximately $15.3 billion), a 24% year-over-year increase, driven by high demand for its GLP-1 drugs, prompting the company to expand manufacturing capacity for sustained competitiveness.
- Diversification Strategy: Novo Nordisk's $4.7 billion acquisition of Akero Therapeutics strengthens its metabolic treatment portfolio, while label expansions for its GLP-1 therapies in cardiovascular and chronic kidney disease treatments enhance clinical versatility, solidifying its competitive position in the healthcare insurance market.
See More
Biogen Advances Alzheimer's Drug to Late-Stage Testing Despite Mixed Results
- Clinical Trial Progress: Biogen announced its plan to advance an experimental Alzheimer's drug to Phase 3 testing despite disappointing mid-stage trial results, as it shows potential in reducing tau protein levels and slowing cognitive decline, particularly at the lowest dose.
- Drug Development Challenges: The company has faced setbacks in its Alzheimer's drug development journey, having successfully launched two drugs to slow cognitive decline, yet its first drug, Aduhelm, was withdrawn due to approval controversies, highlighting market uncertainties.
- Scientific Basis: Biogen's head of development, Dr. Priya Singhal, stated that the latest trial results demonstrate an unprecedented combination of tau reduction and cognitive benefits, emphasizing the necessity to move to Phase 3 testing, indicating progress in dose isolation.
- Competitive Landscape: In the Alzheimer's treatment arena, Biogen faces pressure from rival Eli Lilly, which is also studying drugs aimed at decreasing tau protein levels, underscoring the intense market competition and the urgent demand for innovative therapies.
See More
Bitcoin-Linked Stocks Rise as Starbucks Gets Upgrade
- Bitcoin-Linked Stocks Rise: Bitcoin rose 2% as the Senate Banking Committee discussed a regulatory framework for cryptocurrencies, with Coinbase shares jumping nearly 9%, indicating growing market confidence that could drive future growth for related companies.
- Starbucks Upgrade: TD Cowen upgraded Starbucks from hold to buy, raising its price target from $106 to $120, with analysts noting multiple positive sales drivers in a strong market backdrop, suggesting improved performance ahead.
- Ford Stock Surge: Ford shares rose 7%, adding to a 13% gain from Wednesday, as Morgan Stanley highlighted its energy storage business and partnership with CATL, projecting a $3 billion incremental revenue opportunity for Ford's Model e segment.
- Applied Materials Earnings Outlook: Applied Materials saw a 2% increase in shares ahead of its fiscal second-quarter results, with analysts expecting earnings of $2.66 per share and revenue of $7.68 billion, reflecting sustained optimism about semiconductor equipment demand.
See More
Biogen Advances Alzheimer's Drug to Late-Stage Testing Despite Mixed Results
- Clinical Trial Progress: Biogen announced its plan to advance an experimental Alzheimer's drug into Phase 3 testing despite disappointing mid-stage results, as signals from the lowest dose suggest potential tau reduction and cognitive decline slowing, indicating the drug's development value.
- Mechanism of Action: The drug Diranersen is an antisense oligonucleotide aimed at limiting tau protein production; although higher doses did not show better responses, the efficacy at lower doses provides hope for further research and could pave the way for new Alzheimer's treatments.
- R&D Challenges and Opportunities: Biogen has faced numerous setbacks in developing Alzheimer's drugs, with its first drug Aduhelm withdrawn due to controversy, yet the company remains committed to advancing new therapies, demonstrating resilience in this challenging field.
- Competitive Landscape: As Biogen pushes forward with its drug, rival Eli Lilly is also studying drugs aimed at decreasing tau levels, highlighting the intensifying competition in Alzheimer's treatment, necessitating Biogen to accelerate its R&D efforts to maintain market leadership.
See More
Biogen Completes Acquisition of Apellis Pharmaceuticals
- Acquisition Finalized: Biogen has successfully completed the acquisition of Apellis Pharmaceuticals, which is now a wholly owned subsidiary, significantly enhancing Biogen's market position in nephrology and expected to drive future revenue growth.
- Product Value Addition: Apellis' two products, EMPAVELI® and SYFOVRE®, generated $689 million in net product revenue in 2025, which is anticipated to positively impact Biogen's non-GAAP diluted EPS, enhancing its future profitability.
- Accelerated Market Readiness: The acquisition allows Biogen to leverage Apellis' established commercial and medical infrastructure to expedite the launch readiness for felzartamab, with the first Phase 3 trial readout expected in the first half of 2027.
- Enhanced Shareholder Returns: This transaction is expected to increase Biogen's non-GAAP EPS compound annual growth rate (CAGR), positively impacting its financial performance in 2027 and further boosting investor confidence.
See More
